Genetic variation in MME in relation to neprilysin protein and enzyme activity, Aβ levels, and Alzheimer's disease risk

International Journal of Molecular Epidemiology and Genetics

Volumn 3, Issue 1, 2012, Pages 30-38

  Miners, Scott ^a   van Helmond, Zoë ^a   Barker, Rachel ^a   Passmore, Peter A ^b   Johnston, Janet A ^b   Todd, Stephen ^b   McGuinness, Bernadette M ^b   Panza, Francesco ^c,d   Seripa, Davide ^d   Solfrizzi, Vincenzo ^c   Love, Seth ^a   Prince, Jonathan A ^e   Kehoe, Patrick G ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c UNIVERSITY OF BARI   (Italy)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

amyloid; Alzheimer disease; Association; Gene; MME; Neprilysin; Polymorphism

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; MEMBRANE METALLOENDOPEPTIDASE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FRONTAL CORTEX; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; MALE; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84858711606     PISSN: None     EISSN: 19481756     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Chalmers KA, Barker R, Passmore PA, Panza F, Seripa D, Solfrizzi V, Love S, Prince JA and Kehoe PG. LRP-1 variation is not associated with risk of Alzheimer's disease. Int J Mol Epidemiol Genet 2010; 1: 104-113.
2. Carpentier M, Robitaille Y, DesGroseillers L, Boileau G and Marcinkiewicz M. Declining expression of neprilysin in Alzheimer disease vasculature: possible involvement in cerebral amyloid angiopathy. J Neuropathol Exp Neurol 2002; 61: 849-856.
3. Miners JS, Van Helmond Z, Chalmers K, Wilcock G, Love S and Kehoe PG. Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J Neuropathol Exp Neurol 2006; 65: 1012-1021.
4. Murray IVJ, Proza JF, Sohrabji F and Lawler JM. Vascular and metabolic dysfunction in Alzheimer's disease: a review. Experimental Biology and Medicine 2011; 236: 772-782.
5. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ and Saido TC. Metabolic regulation of brain Abeta by neprilysin. Science 2001; 292: 1550-1552.
6. Shirotani K, Tsubuki S, Iwata N, Takaki Y, Harigaya W, Maruyama K, Kiryu-Seo S, Kiyama H, Iwata H, Tomita T, Iwatsubo T and Saido TC. Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphanand phosphoramidon-sensitive endopeptidases. J Biol Chem 2001; 276: 21895-21901.
7. Eckman EA, Adams SK, Troendle FJ, Stodola BA, Kahn MA, Fauq AH, Xiao HD, Bernstein KE and Eckman CB. Regulation of steady-state beta -amyloid levels in the brain by neprilysin and endothelin-converting enzyme, but not angiotensin-converting enzyme. J Biol Chem 2006; 281: 30471-30478.
8. Hemming ML, Selkoe DJ and Farris W. Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease. Neurobiol Dis 2007; 26: 273-281.
9. Marr RA, Rockenstein E, Mukherjee A, Kindy MS, Hersh LB, Gage FH, Verma IM and Masliah E. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci 2003; 23: 1992-1996.
10. Butler AW, Ng MY, Hamshere ML, Forabosco P, Wroe R, Al-Chalabi A, Lewis CM and Powell JF. Meta-analysis of linkage studies for Alzheimer's disease-a web resource. Neurobiol Aging 2009; 30: 1037-1047.
11. Hamshere ML, Holmans PA, Avramopoulos D, Bassett SS, Blacker D, Bertram L, Wiener H, Rochberg N, Tanzi RE, Myers A, Wavrant-De Vrieze F, Go R, Fallin D, Lovestone S, Hardy J, Goate A, O'Donovan M, Williams J and Owen MJ. Genome-wide linkage analysis of 723 affected relative pairs with late-onset Alzheimer's disease. Hum Mol Genet 2007; 16: 2703-2712.
12. Iwata N, Higuchi M and Saido TC. Metabolism of amyloid-beta peptide and Alzheimer's disease. Pharmacol Ther 2005; 108: 129-148.
13. Blomqvist ME, McCarthy S, Blennow K, Andersson B and Prince JA. Evaluation of neprilysin sequence variation in relation to CSF beta-Amyloid levels and Alzheimer disease risk. Int J Mol Epidemiol Genet 2010; 1: 47-52.
14. Fu Y, Li AF, Shi JJ, Tang MN, Guo YB and Zhao ZH. Lack of association of neprilysin gene polymorphisms with Alzheimer's disease in a southern Chinese community. Int Psychogeriatr 2009; 21: 354-358.
15. Giedraitis V, Kilander L, Degerman-Gunnarsson M, Sundelof J, Axelsson T, Syvanen AC, Lannfelt L and Glaser A. Genetic analysis of Alzheimer's disease in the Uppsala Longitudinal Study of Adult Men. Dement Geriatr Cogn Disord 2009; 27: 59-68.
16. Li H, Wetten S, Li L, St Jean PL, Upmanyu R, Surh L, Hosford D, Barnes MR, Briley JD, Borrie M, Coletta N, Delisle R, Dhalla D, Ehm MG, Feldman HH, Fornazzari L, Gauthier S, Goodgame N, Guzman D, Hammond S, Hollingworth P, Hsiung GY, Johnson J, Kelly DD, Keren R, Kertesz A, King KS, Lovestone S, Loy-English I, Matthews PM, Owen MJ, Plumpton M, Pryse-Phillips W, Prinjha RK, Richardson JC, Saunders A, Slater AJ, St George-Hyslop PH, Stinnett SW, Swartz JE, Taylor RL, Wherrett J, Williams J, Yarnall DP, Gibson RA, Irizarry MC, Middleton LT and Roses AD. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol 2008; 65: 45-53.
17. Lilius L, Forsell C, Axelman K, Winblad B, Graff C and Tjernberg L. No association between polymorphisms in the neprilysin promoter region and Swedish Alzheimer's disease patients. Neurosci Lett 2003; 337: 111-113.
18. Oda M, Morino H, Maruyama H, Terasawa H, Izumi Y, Torii T, Sasaki K, Nakamura S and Kawakami H. Dinucleotide repeat polymorphisms in the neprilysin gene are not associated with sporadic Alzheimer's disease. Neurosci Lett 2002; 320: 105-107.
19. Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, Zismann VL, Joshipura KD, Pearson JV, Hu-Lince D, Huentelman MJ, Craig DW, Coon KD, Liang WS, Herbert RH, Beach T, Rohrer KC, Zhao AS, Leung D, Bryden L, Marlowe L, Kaleem M, Mastroeni D, Grover A, Heward CB, Ravid R, Rogers J, Hutton ML, Melquist S, Petersen RC, Alexander GE, Caselli RJ, Kukull W, Papassotiropoulos A and Stephan DA. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron 2007; 54: 713-720.
20. Sakai A, Ujike H, Nakata K, Takehisa Y, Imamura T, Uchida N, Kanzaki A, Yamamoto M, Fujisawa Y, Okumura K and Kuroda S. Association of the Neprilysin gene with susceptibility to late-onset Alzheimer's disease. Dement Geriatr Cogn Disord 2004; 17: 164-169.
21. Shi J, Zhang S, Tang M, Ma C, Zhao J, Li T, Liu X, Sun Y, Guo Y, Han H, Ma Y and Zhao Z. Mutation screening and association study of the neprilysin gene in sporadic Alzheimer's disease in Chinese persons. J Gerontol A Biol Sci Med Sci 2005; 60: 301-306.
22. Sodeyama N, Mizusawa H, Yamada M, Itoh Y, Otomo E and Matsushita M. Lack of association of neprilysin polymorphism with Alzheimer's disease and Alzheimer's disease-type neuropathological changes. J Neurol Neurosurg Psychiatry 2001; 71: 817-818.
23. Vepsalainen S, Helisalmi S, Mannermaa A, Pirttila T, Soininen H and Hiltunen M. Combined risk effects of IDE and NEP gene variants on Alzheimer disease. J Neurol Neurosurg Psychiatry 2009; 80: 1268-1270.
24. Wood LS, Pickering EH, McHale D and Dechairo BM. Association between neprilysin polymorphisms and sporadic Alzheimer's disease. Neurosci Lett 2007; 427: 103-106.
25. van Helmond Z, Heesom K and Love S. Characterisation of two antibodies to oligomeric Abeta and their use in ELISAs on human brain tissue homogenates. J Neurosci Methods 2009; 176: 206-212.
26. van Helmond Z, Miners JS, Kehoe PG and Love S. Oligomeric Abeta in Alzheimer's Disease: Relationship to Plaque and Tangle Pathology, APOE Genotype and Cerebral Amyloid Angiopathy. Brain Pathol 2010; 20: 468-480.
27. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G and Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-486.
28. McKhann G, Drachman D, Folstein M, Katzman R, Price D and Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
29. Wenham PR, Price WH and Blandell G. Apolipoprotein E genotyping by one-stage PCR. Lancet 1991; 337: 1158-1159.
30. Miners JS, Baig S, Tayler H, Kehoe PG and Love S. Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity. J Neuropathol Exp Neurol 2009; 68: 902-914.
31. Miners JS, Verbeek MM, Rikkert MO, Kehoe PG and Love S. Immunocapture-based fluorometric assay for the measurement of neprilysinspecific enzyme activity in brain tissue homogenates and cerebrospinal fluid. J Neurosci Methods 2008; 167: 229-236.
32. Barrett JC, Fry B, Maller J and Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
33. Hill WG. Estimation of linkage disequilibrium in randomly mating populations. Heredity 1974; 33: 229-239.
34. Miners JS, van Helmond Z, Kehoe PG and Love S. Changes with Age in the Activities of betasecretase and the Abeta-degrading Enzymes Neprilysin, Insulin-degrading Enzyme and Angiotensin-converting Enzyme. Brain Pathol 2010; 20: 794-802.
35. Miners JS, van Helmond ZK, Chalmers K, Wilcock GK, Love S and Kehoe PG. Downregulation of neprilysin in Alzheimer's disease is associated with cerebral amyloid angiopathy and APOE ε4. JNEN 2006; submitted.
36. van Helmond Z, Miners JS, Kehoe PG and Love S. Higher Soluble Amyloid beta Concentration in Frontal Cortex of Young Adults than in Normal Elderly or Alzheimer's Disease. Brain Pathol 2010; 20: 787-793.
37. Clarimon J, Munoz FJ, Boada M, Tarraga L, Sunyer J, Bertranpetit J and Comas D. Possible increased risk for Alzheimer's disease associated with neprilysin gene. J Neural Transm 2003; 110: 651-657.
38. Helisalmi S, Hiltunen M, Vepsalainen S, Iivonen S, Mannermaa A, Lehtovirta M, Koivisto AM, Alafuzoff I and Soininen H. Polymorphisms in neprilysin gene affect the risk of Alzheimer's disease in Finnish patients. J Neurol Neurosurg Psychiatry 2004; 75: 1746-1748.
39. Yamada M, Sodeyama N, Itoh Y, Takahashi A, Otomo E, Matsushita M and Mizusawa H. Association of neprilysin polymorphism with cerebral amyloid angiopathy. J Neurol Neurosurg Psychiatry 2003; 74: 749-751.
40. Coon KD, Myers AJ, Craig DW, Webster JA, Pearson JV, Lince DH, Zismann VL, Beach TG, Leung D, Bryden L, Halperin RF, Marlowe L, Kaleem M, Walker DG, Ravid R, Heward CB, Rogers J, Papassotiropoulos A, Reiman EM, Hardy J and Stephan DA. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry 2007; 68: 613-618.
41. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanche H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alperovitch A, Lathrop M and Amouyel P. Genome -wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009; 41: 1094-1099.
42. Kehoe PG, Miners S and Love S. Angiotensins in Alzheimer's disease friend or foe? Trends Neurosci 2009; 32: 619-628.
43. Miners JS, Ashby E, Van Helmond Z, Chalmers KA, Palmer LE, Love S and Kehoe PG. Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 2008; 34: 181-193.
44. Miners JS, Raiker M, Love S and Kehoe PG. ACE variants and association with brain Aβ levels in Alzheimer's disease. American Journal of Translational Research 2010; 3: 8.
45. Ruitenberg A, den Heijer T, Bakker SL, van Swieten JC, Koudstaal PJ, Hofman A and Breteler MM. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann Neurol 2005; 57: 789-794.
46. Warkentin S, Erikson C and Janciauskiene S. rCBF pathology in Alzheimer's disease is associated with slow processing speed. Neuropsychologia 2008; 46: 1193-1200.
47. Kehoe PG, Russ C, McIlory S, Williams H, Holmans P, Holmes C, Liolitsa D, Vahidassr D, Powell J, McGleenon B, Liddell M, Plomin R, Dynan K, Williams N, Neal J, Cairns NJ, Wilcock G, Passmore P, Lovestone S, Williams J and Owen MJ. Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. Nat Genet 1999; 21: 71-72.
48. Lehmann DJ, Cortina-Borja M, Warden DR, Smith AD, Sleegers K, Prince JA, van Duijn CM and Kehoe PG. Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease. Am J Epidemiol 2005; 162: 305-317.
49. Belbin O, Brown K, Shi H, Medway C, Abraham R, Passmore P, Mann D, Smith AD, Holmes C, McGuinness B, Craig D, Warden D, Heun R, Kolsch H, Love S, Kalsheker N, Williams J, Owen MJ, Carrasquillo M, Younkin S, Morgan K and Kehoe PG. A multi-center study of ACE and the risk of late-onset Alzheimer's disease. J Alzheimers Dis 2011; 24: 587-597.
50. Kehoe PG. Angiotensins and Alzheimer's disease: a bench to bedside overview. Alzheimers Res Ther 2009; 1: 3.
51. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P and Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346.